Year: 2024
Type: article
Abstract: The Treatment Advocacy Center (TAC) and other advocates are trying to convince the Food and Drug Administration (FDA) to end the Risk Evaluation and Mitigation Strategy (REMS) requirements for clozapine. The requirements, they said, reduce the number of providers who will prescribe this “gold standard medication” that works for many people with serious mental illness.
Source: Mental Health Weekly
DOI: 10.1002/mhw.34216
Author: Valerie A. Canady
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4403536937